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Abstract: Although lung cancer therapy has slowly improved with
standard cytotoxic chemotherapy drugs, we have reached an efficacy
plateau. The addition of targeted agents, such as those with antian-
giogenesis activity, to chemotherapy can improve response and
survival outcomes. The first of these agents to gain approval in lung
cancer in October 2006 was the antivascular endothelial growth
factor antibody, bevacizumab. Small molecule tyrosine kinase in-
hibitors targeting the vascular endothelial growth factor receptor also
have proven activity and are under active investigation. Vascular
disrupting agents target existing tumor vasculature leading to tumor
necrosis, and are being studied in solid tumors, including lung cancer,
both as single agents and in combination with chemotherapy. This
article will review these new targeted antiangiogenic and antivascular
agents with a focus on their use as lung cancer therapeutics.
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Lung cancer is the leading cause of cancer-related death inthe United States, with an estimated 215,020 new cases
and 161,840-related deaths in 2008.1 Despite advances in
treatment, nearly 80% of lung cancer cases are diagnosed at
advanced stages (IIIB or IV), and the 5-year survival rate has
not exceeded 15%.1,2 Current chemotherapeutic options are
not curative in advanced stage disease but provide some
benefit in survival and quality of life.3 For the past few years,
novel vascular-targeted agents with activity in different can-
cer pathways have been emerging. The most developed, with
survival benefit demonstrated in a randomized trial, are the
angiogenesis inhibitors.4
In October 2006, the antiangiogenic agent bevacizumab
was granted a labeling extension by the US Food and Drug
Administration for the first-line treatment of advanced,
nonsquamous, non-small cell lung cancer (NSCLC) in com-
bination with platinum-based chemotherapy.4 Nevertheless,
the prognosis for patients with lung cancer remains poor, and
agents with greater activity are needed. Other vascular-tar-
geted agents are being investigated in trials for the treatment
of NSCLC and small cell lung cancer (SCLC). This article
focuses on these new targeted drugs, including antiangio-
genic agents and tumor-vascular disrupting agents.
ANTIANGIOGENIC AGENTS
Solid tumor growth and metastases depend on develop-
ment of new vasculature (neovascularization). Blocking angio-
genesis inhibits tumor growth and metastasis and is thus a valid
treatment strategy,5–8 as first hypothesized by Folkman7 over 30
years ago.
The most active angiogenic cytokines are vascular
endothelial growth factor (VEGF), fibroblast growth factor,
hepatocyte growth factor, transforming growth factors- and
-, platelet-derived growth factor (PDGF), tumor necrosis
factor- (TNF-), and interleukin-8.9–11 The VEGF family
plays a key proangiogenic role in vascular development12 by
inducing endothelial cell proliferation, protease expression,
cell migration, vascular permeability, and vascular immatu-
rity.13,14 VEGF ligand is secreted by tumor cells and macro-
phages. Studies have found that VEGF is expressed in 42 to
75% of NSCLC, and increased VEGF expression is associ-
ated with poor prognosis.15 Three cell surface receptors have
been identified [VEGF receptor (VEGFR)-1, VEGFR-2, and
VEGFR-3].16,17 VEGFR-2 is the key receptor in angiogenesis
because its activation leads to endothelial cell proliferation,
survival, and migration. VEGFR-1 plays a regulatory role
through VEGF sequestration or stimulation of hematopoietic
stem-cell migration. VEGFR-3 mediates lymphangiogenesis
and has been associated with lymph node metastasis. Both
VEGFR-1 and VEGFR-2 activation in tumors are involved in
the recruitment of endothelial cell precursors to the develop-
ing tumor vasculature.18
The first antiangiogenic agents developed target either
VEGF directly or VEGFR. They inhibit neovascularization,
thereby limiting tumor growth. Modification of tumor vascu-
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lature, allowing for improved chemotherapy delivery, has
also been hypothesized.19
ANTI-VEGF AGENTS
The original classes of antiangiogenic agents are mole-
cules, mostly antibodies, which target the VEGF pathway (Table
1). The largest class is the tyrosine kinase inhibitors (TKIs) that
block VEGFR-2, among other targets (Table 2).20–24
Molecules Targeting the VEGF Ligand
Bevacizumab, a recombinant humanized monoclonal
antibody directed against VEGF, is the first antiangiogenic
agent to demonstrate efficacy in solid tumors.25 It has been
approved for treatment of nonsquamous NSCLC in combi-
nation with carboplatin and paclitaxel in the United States
and in combination with any chemotherapy doublet in the
European Union.
A phase II trial of patients with newly diagnosed
NSCLC compared carboplatin plus paclitaxel with or without
bevacizumab (7.5 or 15 mg/kg). In this trial, the primary end
point was time to progression (TTP), and the 15 mg/kg bevaci-
zumab arm showed not only an improvement in TTP but also
increased response rate (RR) and a trend in overall survival (OS)
benefit and was taken forward into phase III testing. However,
patients with central tumors or squamous cell histology had a
higher risk of fatal bleeding.26 In addition, it is worth noting that
the 7.5 mg/kg bevacizumab arm had higher numbers of squa-
mous cell patients and increased fatal hemoptysis, which ad-
versely affected survival.
The subsequent phase III trial, Eastern Cooperative
Oncology Group 4599, evaluated a combination of carbopla-
tin (AUC  6 every 3 weeks) and paclitaxel (200 mg/m2
every 3 weeks) for 6 cycles with or without bevacizumab (15
mg/kg every 3 weeks) in patients with untreated advanced
NSCLC.4 Because of the risk of bleeding, this trial excluded
patients with squamous cell histology, brain metastases, an-
ticoagulation therapy, and history of gross hemoptysis. The
study enrolled 878 patients and found an increase in median
survival (10.3 versus 12.3 months; p  0.003, hazard ratio
(HR  0.79, p  0.003)), progression-free survival (PFS: 4.5
versus 6.2 months; p  0.001, HR  0.66, 0.001), and RR
(15% versus 35%; p 0.001) in favor of the bevacizumab arm.
In this trial, the most common adverse event (AE) was bleeding
in the bevacizumab arm (0.7% versus 4.4%; p 0.001). Fifteen
treatment-related deaths occurred in the bevacizumab arm,
including five incidents of pulmonary hemorrhage, five epi-
sodes of febrile neutropenia, two gastrointestinal bleeding
events, two cerebrovascular events, and one pulmonary em-
bolus. Other AEs were grade three hypertension (1% versus
7%), and grade 3 neutropenia (17% versus 26%) in the
placebo arm and bevacizumab arm, respectively (p  0.05).4
In a subgroup analysis, men in the bevacizumab arm had a
greater survival benefit than women,27 though in a recent
reanalysis of the data, women aged60 years had substantial
survival benefit with bevacizumab.28 Following this trial,
bevacizumab was approved for treatment of first-line NSCLC
in combination with carboplatin and paclitaxel. However,
because of the safety concerns raised in the phase II trials, it
was not indicated for patients with squamous histology, those
with brain metastases, or on anticoagulation,29 though the
restrictions on brain metastases and anticoagulation are being
lifted with more recent data.30
A second phase III trial, AVAIL, used a different
chemotherapy regimen and included patients with untreated
or recurrent nonsquamous NSCLC without brain metastasis
or tumor invasion into major vessels (though central tumors
were allowed).31 This trial, in contrast to E4599, was placebo
TABLE 1. Antibodies and Other Constructs Targeting the
VEGF Pathway
Molecule VEGF VEGFR-1 VEGFR-2
Bevacizumab   
Rh-Endostatin   
VEGF Trap   
Ramucirumab (IMC 1121B)   
IMC18F1   
VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth
factor receptor.
TABLE 2. Small Molecule Inhibitors of VEGF Receptors
Inhibitors VEGFR-1 VEGFR-2 VEGFR-3 PDGFR c-kit EGFR Other
AZD2171 (Cediranib)      
BAY43-9006 (Sorafenib)       raf, ret, FGFR
Sunitinib       ret, FGFR
AMG-706 (Motesanib)     ret
ZD6474 (Vandetanib)    /   ret
Axitinib      
PTK787 (Valatanib)       cFms
BIBF1120     FGFR
XL-647     Her-2
GW786034 (Pazopanib)    
ABT-869     
VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; EGFR, epithelial growth factor receptor; FGFR, fibroblast growth factor
receptor.
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controlled. In this trial, 1043 patients were enrolled in 3 arms.
All patients received cisplatin  gemcitabine with placebo or
bevacizumab at 7.5 or 15 mg/kg. Each of the bevacizumab
arms were compared separately to placebo, but the trial was
not designed to directly compare the two doses of bevaci-
zumab. An improvement in the primary end point of PFS was
observed in both bevacizumab arms (6.5 versus 6.7 versus 6.1
months in the 15 mg/kg, 7.5 mg/kg, and placebo arms,
respectively, p  0.003). The RR was also significantly
improved in the bevacizumab arms (30% versus 34% versus
20% in 15 mg/kg, 7.5 mg/kg, and placebo arms, respec-
tively). The incidence of hemoptysis, neutropenia, hyperten-
sion, vomiting and epistaxis were higher in the bevacizumab
arms. This trial did not, however, show a significant OS
benefit with median OS of 13.4, 13.6, and 13.1 months,
respectively, in the 15 mg/kg, 7.5 mg/kg, and placebo
arms.31,32 Despite the conflicting results in OS benefit in the
two studies, the response and PFS benefit persist in both
studies. Based on these trials, bevacizumab is approved in the
United States with a dose of 15 mg/kg in combination with
carboplatin/paclitaxel and in Europe at either 7.5 or 15 mg/kg
with cisplatin-based combination chemotherapy. Special pa-
tient populations including the elderly and those with brain
metastases will be discussed later.
Bevacizumab has also been studied in combination
with other agents including erlotinib. BeTA, a phase III trial,
randomized patients with advanced NSCLC after failure of a
standard first-line chemotherapy (excluding prior bevaci-
zumab therapy) to receive erlotinib (150 mg daily)  bev-
acizumab (15 mg/kg every 3 weeks) or placebo. In this trial,
the primary end point was to analyze OS. A total of 636
patients were enrolled. Activity of the combination was
demonstrated, with a median PFS of 3.4 months versus 1.7
months (HR  0.62, p  0.001), and an objective response
rate (ORR) of 12.6% versus 6.2%, p 0.006, in the erlotinib
bevacizumab and erlotinib  placebo arms, respectively.
However, the trial failed to meet its primary end point, with
similar median OS between the two arms (9.3 and 9.2 months for
erlotinib  bevacizumab and erlotinib  placebo, respectively).33
The ATLAS trial (n  1160) also looked at the com-
bination of bevacizumab and erlotinib but from the perspec-
tive of adding erlotinib to bevacizumab for patients receiving
maintenance bevacizumab after completion of 4 cycles of
chemotherapy  bevacizumab. No new safety signals were
seen, and the primary end point of PFS improvement was met
(HR  0.72 [p  0.0012]).34 Combinations of bevacizumab
with other agents have been investigated in phase II studies,
including docetaxel and carboplatin, oxaliplatin and pem-
etrexed, pemetrexed and carboplatin, docetaxel and gemcit-
abine, cisplatin and docetaxel, cisplatin and irinotecan, and
nanoparticle albumin-bound paclitaxel and carboplatin.35–40
A four-drug regimen of bevacizumab, carboplatin, pac-
litaxel, and cetuximab is under active investigation in the
Southwest Oncology Group. In phase II trial, 110 patients
with advanced NSCLC received carboplatin AUC 6, pacli-
taxel 200 mg/m2, bevacizumab 15 mg/kg IV day 1 every 3
weeks, and cetuximab 400 mg/m2 day 1 then 250 mg/m2
weekly for up to 6 cycles with continuation of the bevaci-
zumab and cetuximab until progression.41 In this trial, PFS
was 7 months, OS was 14 months, and the grade 4 hemor-
rhage was 2%.
Given the potential for toxicity with bevacizumab,
subset analyses of the elderly have been evaluated separately.
In the E4599 study, in a subset analysis that was not statis-
tically significant, addition of bevacizumab in patients 70
years of age did not result in the same survival advantage as
their younger counterparts, though RR and PFS improved.42
Elderly patients experienced more neutropenia (34% versus
22%), bleeding (7.9% versus 3.2%), proteinuria (7.9% versus
1.3%), muscle weakness (7.9% versus 2.2%), and motor
neuropathy (3.5% versus 0.6%) with carboplatin paclitaxel
bevacizumab than younger. In contrast, in the AVAIL trial,
the PFS benefit from bevacizumab is similar in patients
younger and older than 65 years, and no differential toxicity
was seen in the older patients.43
In trials including patients with brain metastases (ATLAS
and PASSPORT), no significant bleeding risk has been iden-
tified in patients treated with bevacizumab after local therapy
for brain metastases.30,44 Therefore, current guidelines sug-
gest that bevacizumab can be considered in patients with
treated, stable brain metastases. Results in squamous cell
patients have continued to be concerning with bleeding sig-
nals seen after radiation or stabilizing chemotherapy.45
Studies investigating use of bevacizumab in earlier
stages of disease are ongoing. They include trials of patients
with stage III disease treated in combination with radiation
therapy. Toxicity concerns, such as bleeding and fistula
formation, have been raised in these trials. The Eastern
Cooperative Oncology Group is leading a multinational effort
with the E1505 study, which evaluates the addition of bev-
acizumab to adjuvant chemotherapy in resected stage IB–IIIA
NSCLC.46 Preclinical studies have raised the concern that
antiangiogenic agents used in the adjuvant setting could lead
to resistance mechanisms that may increase the propensity of
a tumor to metastases.47,48 However, this data are preliminary
and will need to be supported with additional research before
altering clinical trials currently underway.
Encouraging phase II, nonrandomized trials of bevaci-
zumab in SCLC have led to the ongoing phase II trial,
SALUTE,49 which randomizes patients with untreated SCLC
to chemotherapy with or without bevacizumab.
Other anti-VEGF antibody strategies are in develop-
ment, including the humanized monoclonal antibodies IMC-
1121B (Ramucirumab, Imclone Systems) and IMC-18F1,
which target the extracellular domain of VEGFR-2 and
VEGFR-1, respectively.50,51 Both of these agents are in early
stages of development.
Another anti-VEGF pathway approach is Rh-Endosta-
tin (Endostar, YH-16), an endogenous collagen XVIII frag-
ment with antiangiogenic properties, which reduces the ex-
pression of VEGF.52 A phase II trial randomized patients to
two groups to receive 7.5 mg/m2 or 15 mg/m2 of Rh-
Endostatin. Sixty-eight patients were included, the RR was
3.0% in both groups (p 0.05), the median TTP was 60 days
versus 71 days (p  0.05), and the AEs were 48.6% versus
38.7% (p  0.05).53 A phase III trial using cisplatin and
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vinorelbine as the chemotherapy backbone demonstrated an
improved RR (35.4% versus 19.5%, p 0.003) and TTP (6.3
months versus 3.6 months, p 0.001) with the drug,54 and an
ongoing trial is now exploring combination therapy with
carboplatin  paclitaxel.55
VEGF Trap (Aflibercept) is a human, soluble VEGF
receptor decoy that combines components of VEGFR-1 and
VEGFR-2 fused to the Fc portion of immunoglobulin G1 in
a chimeric molecule. Some single-agent activity of the drug
was demonstrated in a phase II trial,56 and multiple phase II
combination trials using the agent are ongoing in nonsqua-
mous NSCLC. A phase III study (VITAL) comparing do-
cetaxel with or without Aflibercept in second line is also
recruiting patients.57
Multikinase Inhibitors
The largest class of anti-VEGF pathway agents is the
TKIs that inhibit VEGFR. TKIs are small molecules, most of
which bind to the ATP-binding site of the receptor, thus
inhibiting activation and downstream signaling. In addition to
inhibiting VEGFR-2, antiangiogenic TKIs have multiple
other targets, leading to the variable toxicity and efficacy
results seen to date. Although some have single-agent activ-
ity, the results of chemotherapy combination trials with them
have so far been disappointing.
Vandetanib (ZD6474, Zactima) is an oral anilinoquina-
zoline that inhibits VEGFR-1, VEGFR-2, VEGFR-3, RET,
and EGFR (Table 2).58 A phase I study of 77 patients
identified a maximum tolerated dose of 300 mg daily. Hy-
pertension and QTc prolongation were the most common
AEs.59 No unexpected toxicities were seen in phase I/II
combination trials with pemetrexed or docetaxel.60 In a ran-
domized phase II study versus gefitinib in 168 patients, PFS
was 11 weeks and 8.1 weeks for vandetanib and gefitinib,
respectively. Grade 3/4 AEs were diarrhea (8.4%) and rash
(4.8%).61 Another phase II study tested 3 arms (arm A:
vandetanib 100 mg  docetaxel, arm B: vandetanib 300 mg 
docetaxel, and arm C: docetaxel alone) in 127 patients with
NSCLC previously treated with platinum-based chemother-
apy. The median PFS was 18.7, 17, and 12 weeks for arms A,
B, and C, respectively (p  0.037), in favor of the two arms
with vandetanib.62 These results led to four recently com-
pleted phase III trials, ZEST, ZEAL, ZEPHYR, and ZODIAC.
ZODIAC and ZEAL were second-line trials of docetaxel
or pemetrexed, respectively, with or without vandetinib.
ZODIAC enrolled 1391 patients, who received vandetanib 
docetaxel or placebo  docetaxel. Addition of vandetanib to
docetaxel showed a statistically significant improvement in
PFS versus docetaxel (HR  0.79, 98% confidence interval
0.70–0.90; p  0.001), in RR (17% versus 10%, p  0.001),
and time to deterioration of symptoms (HR  0.78, p 
0.002). OS was better in the vandetanib arm but was not
statistically significant (HR  0.91, p  0.196). The AEs
increased in the vandetanib arm were diarrhea (42% versus 33%),
rash (42% versus 24%) and neutropenia (32% versus 27%),
and hypertension (6% versus 2%). AEs that were less fre-
quent in the vandetanib arm were nausea (23% versus 32%),
vomiting (16% versus 21%), and anemia (10% versus
15%).63 It is unclear why a reduction in toxicity was seen,
though preclinical data showing increased hematopoeisis in
the setting of VEGF inhibition has been described.64 ZEAL
enrolled 534 patients, who were randomized to receive van-
detanib  pemetrexed or placebo  pemetrexed. There were
positive trends seen for vandetanib  pemetrexed for both
PFS (p  0.108) and OS (p  0.219), but the study failed to
find a statistically significant improvement in either outcome
with the addition of vandetanib to pemetrexed. Why the
ZODIAC trial found a statistically significant PFS benefit, but
the ZEAL trail did not is a matter of debate and may be due
to the smaller size of the ZEAL trial. There was no increase
in bleeding or thrombotic events in the vandetanib arm of
ZEAL.65 A direct comparison of vandetinib to erlotinib
(ZEST) found equivalent PFS and OS.66 Results are not yet
known for the ZEPHYR study that randomized patients to
vandetinib or placebo. In SCLC, this molecule failed to show
a benefit in survival67 or was a PFS benefit found in a
randomized phase II study when added to first line carboplatin
paclitaxel.
Cediranib (AZD2171) inhibits VEGFR-1, VEGFR-2,
VEGFR-3, platelet-derived growth factor receptor (PDGFR)-,
and c-kit (Table 2).68 As a single agent, the drug is well
tolerated at doses up to 45 mg daily. Toxicities in a phase I
monotherapy trial were hypertension, headache, diarrhea, and
voice hoarseness.69 In phase II chemotherapy combination
trials in patients with previously untreated advanced stage
NSCLC, RR was high (45%) and toxicities included fatigue,
diarrhea, febrile neutropenia, mucositis, anorexia, and hyper-
tension, with increased toxicity associated with daily doses
greater than 45 mg.70 A National Cancer Institute-Canada
phase II/III trial of carboplatin  paclitaxel with or without
cediranib, BR.24, found the combination active (with a signifi-
cantly increased RR of 38% versus 16% a trend for an improved
survival HR  0.78, p  0.11)71 but too toxic even at 30 mg,
causing suspension of the phase III portion of the trial. The
BR.29 study was recently opened using the same phase II/III
design but with a 20 mg dose of cediranib. Combinations with
cediranib and gefitinib in SCLC are also ongoing.
Sorafenib (Nexavar) inhibits RAF, VEGFR-1,
VEGFR-2, VEGFR-3, PDGFR-, Flt-3, c-kit, and p38-
(Table 2)72,73 and has proven activity in renal cell carcinoma74
and hepatocellular carcinoma.75 The commonly used dose of
400 mg twice daily is associated with diarrhea and skin
toxicities (hand-foot syndrome). Single-agent activity in
NSCLC is limited, though prolongation of disease stability
has been observed. In a monotherapy trial in untreated stage
IIIB/IV NSCLC (n 20), ORR was 12%, disease control rate
was 40%, and median survival was 8.8 months. Grade 3 AEs
included fatigue (20%), diarrhea (8%), and dyspnea (8%),
and there was one episode of grade 4 pulmonary hemor-
rhage.76 Trials of the drug in patients with NSCLC who had
received prior therapy reported similar toxicity profiles with
RR 0 to 13%, disease stability 50%, and PFS around 5
months.77–80 Most recently, a large phase II trial, using a
randomized discontinuation design provided more definitive
evidence for single-agent activity of sorafenib. E2501 en-
rolled more than 300 patients and compared sorafenib with
placebo in patients with NSCLC after failure with two prior
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regimens of chemotherapy. After a 2-month lead-in period
during which all patients received active drug, those with
stable disease (n  83) were randomized to sorafenib or
placebo. Twenty-four patients had stable disease or a partial
response after 2 additional months of sorafenib compared
with only six in the placebo arm. The median PFS was 3.6
and 2 months in the sorafenib and placebo arms, respectively
(p  0.01). Grade 5 AEs were renal failure (n  1) and
pulmonary hemorrhage (n  1). Grade 4 cerebrovascular
ischemia events (n  4) were noted. The other AEs were
fatigue, hand-foot reaction, and rash.81 A randomized phase
III trial of sorafenib versus placebo in patients with prior
chemotherapy is currently underway. Another trial tested
sorafenib in NSCLC with k-ras mutation with encouraging
results in a small number of patients.82
Combination trials with sorafenib have been less en-
couraging. In combination with gefitinib, sorafenib (400 mg)
did not increase RR over that seen with gefitinib alone and
9% of patients discontinued the trial due to toxicity, partic-
ularly hypertension.83 When sorafenib was combined with
erlotinib though in a randomized phase II study for previously
treated advanced stage NSCLC trial, the PFS was 3.1 months
versus 1.87 months (p  0.06) in the erlotinib  sorafenib
arm, and erlotinib  placebo arm, respectively. There were
more AEs in the sorafenib arm, and no increase in RR was
observed.84 In a phase III trial of 926 chemotherapy-naive
patients with stage IIIB/IV NSCLC randomized to receive
carboplatin  paclitaxel with or without sorafenib, sorafenib
failed to show an improvement in survival. Furthermore,
greater toxicities were observed in the sorafenib arm, partic-
ularly in patients with squamous histology. Thirteen patients
had a fatal pulmonary hemorrhage.85 A similar phase III trial
(NEXUS), but with a restriction to patients with nonsqua-
mous histology, used cisplatin gemcitabine with or without
sorafenib and completed accrual in February 200986 with
results pending. Trials in SCLC are ongoing with cisplatin or
topotecan.
Sunitinib (SU11248, Sutent) is an oral multitarget TKI
against VEGFR-1, VEGFR-2, PDGFR, c-kit, and FLT-3
(Table 2) approved by the US Food and Drug Administration
for the treatment of renal cell carcinoma and refractory
gastrointestinal stromal tumors. Dose-limiting toxicities ob-
served in phase I trials were asthenia, hypertension, and
bullous skin toxicity.87 In phase II, single-agent trials in
NSCLC, toxicities were as expected but with the addition of
pulmonary hemorrhage, which was fatal in at least 1 pa-
tient.88,89 Single-agent activity (ORR  9.5%) was seen with
an intermittent dosing schedule (4 weeks on/2 weeks
off).88–91 In a randomized phase II study of patients with
nonsquamous NSCLC treated with carboplatin  paclitaxel 
bevacizumab with or without sunitinib, there were 5 deaths of
56 patients.92 Although the toxicity in combination with
first-line chemotherapy is concerning, the single-agent activ-
ity of the compound is very encouraging, and the Cancer and
Leukemia Group B is planning a large phase III maintenance
trial after completion of first-line chemotherapy. In the
planned trial of 240 patients, patients will be randomized to
receive sunitinib at 37.5 mg orally daily or placebo after
completion of first-line chemotherapy. Three other phase II
studies with sunitinib are in development within the Cancer
and Leukemia Group B including a second line trial of
pemetrexed (500 mg/m2 every 3 weeks), sunitinib (37.5 mg
orally daily continuously), or both agents. In SCLC, a phase
II trial is ongoing for extensive disease in first or second line.
Motesanib (AMG 706) is an oral multikinase inhibitor
against VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, RET, and
c-kit (Table 2). This molecule was analyzed in a phase I study
in patients with advanced solid tumor with a maximum
tolerated dose of 125 mg daily.93 Combination trials of the
drug with panitumumab and carboplatin  paclitaxel or
panitumumab with cisplatin  gemcitabine have been con-
ducted with grade 3/4 AEs of fatigue (45%), hypertension
(27%), dyspnea (9%), sinusitis (9%), and pulmonary embo-
lism (9%).94,95 Currently, a phase III trial in combination with
carboplatin  paclitaxel is ongoing.96 This trial was closed
for higher early mortality and a higher rate of hemoptysis in
patients with squamous histology, then reopened with exclu-
sion of this patient population.96
Axitinib (AG-013736) is a small molecule that inhibits
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and c-kit (Table
2). In a phase I study, the maximum tolerated dose was 5 mg
twice daily, with AEs including hypertension, seizure, eleva-
tion of liver tests, and mesenteric vein thrombosis with
pancreatitis.97 A phase II trial testing the efficacy and safety
of axitinib in NSCLC as a single agent showed in 32 patients,
a RR of 41%, PFS of 4.9 months, and a median OS of 14.8
months. The most common grade 3 AEs were fatigue (22%),
hypertension (9%), and hyponatremia (9%).98 Currently, a
phase III trial of single-agent axitinib in advanced NSCLC is
ongoing.
Vatalanib (PTK787, ZK-222584) inhibits VEGFR-1,
VEGFR-2, VEGFR-3, PDGFR, c-kit, and c-Fms with AEs
including fatigue, dizziness, vomiting, hypertension, ataxia,
and dyspnea (Table 2).99 In a phase II monotherapy trial in
previously treated NSCLC, the agent had a moderate efficacy
with a RR of 10%, and an OS of 7 months, but three fatalities
occurred (two pulmonary hemorrhages and one pulmonary
embolism).100 Another phase II trial in pretreated NSCLC
using dynamic contrast-enhanced magnetic resonance imag-
ing showed a statistically significant reduction in tumor
vascular parameters.101
Pazopanib (GW786034) was tested in patients with
stage I/II NSCLC treated for 2 to 6 weeks before surgery.
Twenty of 23 patients (87%) had reduction of the tumor
volume, and three had partial response. Further, treatment
was associated with decreases in soluble VEGFR-2
(sVEGFR-2), and a strong correlation existed between
sVEGFR-2 changes and tumor shrinkage (Table 2).102
Another small molecule with potential antiangiogenic
effects is enzastaurin (LY317615), a competitive selective
inhibitor of protein kinase C- and PI3K/AKT. Extensive
phases I and II testing of the compound in combination with
chemotherapeutics and biologics such as erlotinib has been
conducted with fatigue reported as the predominant toxicity.103
Results from two of the phase II trials that tested enzastaurin
in combination with chemotherapy were presented at the
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2009. The first trial compared carboplatin  pemetrexed 
bevacizumab with or without enzastaurin in nonsquamous
stage IIIB/IV NSCLC and the second compared carboplatin 
pemetrexed with or without enzastaurin versus carboplatin 
docetaxel in stage IIIB/IV NSCLC as first-line therapy. Nei-
ther of these trials showed a significantly prolonged PFS in
the enzastaurin arm.104,105 A phase II study included 48
patients with advanced NSCLC previously treated by one or
two prior regimens. All patients received erlotinib 150 mg
and enzastaurin 500 mg daily and orally. The addition of
enzastaurin to erlotinib did not improve the RR and the
disease control rate. PFS and OS are pending. The main AEs
were rash (70%), diarrhea (55%), fatigue (25%), and
nausea (25%).106
Other VEGFR-TKIs in early stages of development
include BIBF 1120, XL647 (which has more EGFR-TKI
activity), CP-547,632, E7080, AEE788, KRN951, ABT-869,
OSI-930, and BMS-690514, among others (Table 2).
TUMOR-VASCULAR DISRUPTING AGENTS
Another approach to anticancer therapy is direct dis-
ruption of the existing tumor vasculature, as opposed to
targeting neovascularization as previously discussed. Com-
pared with normal vasculature, the structure of tumor blood
vessels is abnormal, with irregular blood flow, increased
permeability related to immaturity, and disorganization of the
vessels.107 These differences provide the opportunity for
selective activity against the vessels supplying the tumor with
oxygen and nutrients.
The first beneficial effects of vascular disrupting
agents, vessel occlusion, inhibition of blood flow and necro-
sis, were identified in 1932 with the use of colchicine by
Dominici.108 Because of toxicity, development of colchicine
as an antineoplastic was halted until the 1980s when two
classes of vascular disrupting agents were studied that target
established tumor blood vessels and the related vascular
endothelial cells.109
Vascular disrupting agents are composed of flavonoids
[flavone-8-acetic acid (FAA), LM985, ASA404 (DMXAA
AS1404 or ASA404, Novartis International AG, Basel, Swit-
zerland)], tubulin-binding drugs [Combretastatin A4 (CA4P),
ZD6126 (AstraZeneca, San Francisco, CA), ABT-751 (Ab-
bott, Il), and other agents, including Thalidomide, analogues
of Thalidomide (Celgene, Summit, NJ), AVE8062 (Ajino-
moto Company, Japan), Exherin TM (ADH-1, Adherex, Ot-
tawa, Ontario), OXi4503 (Oxygene Inc., Baltimore, MD),
Dolastatin 10 (Pierre Fabre Medicament, Boulogne Billan-
court, France), and Auristatin (Seattle Genetics, Seattle,
WA)] (Table 3).24,109–112
Flavonoids
FAA and its ester (LM095) were the first drugs reported
to have activity as vascular disrupting agents. FAA, the
precursor of ASA404 (DMXAA), caused a selective shut-
down of tumor blood flow with this action apparently related
to the production of TNF-.113–115
Another compound, LM985, demonstrated a dose-lim-
iting toxicity of reversible hypotension at 1500 mg/m2 ad-
ministered intravenously every 3 weeks with other toxicities
including urticarial rash, muscle aches, flushing, hypotension,
diarrhea, nausea, vomiting, and cholestatic jaundice but no
clear activity.116,117
ASA404 [DMXAA (5,6-dimethylxanthenone-4 acetic
acid)] works by disrupting the actin cytoskeleton of tumor
vascular endothelial cells, making tumor vasculature more
permeable. ASA404 has a dual mechanism of action (direct
and indirect). The direct action induces apoptosis in tumor
vascular endothelial cells within 30 minutes, which must be
kept in mind when considering combination therapy. The
indirect action is associated with an increase of TNF-, nitric
oxide, and other cytokines, which can be enhanced with the
combination with chemotherapy.118,119 Precursors to the com-
pound were initially discovered due to their induction of
hemorrhagic necrosis in murine tumors. ASA404 induces
apoptosis of tumor endothelial cells. Additional mechanisms
of action are an increase of TNF- and production of nitric
oxide. This, in turn, induces a relaxation of the vascular
smooth muscle, causing an increase in vascular permeability.120–122
In phase I testing, the dose-limiting toxicities were visual
disturbances, dizziness, headaches, anxiety, urinary inconti-
nence, tumor pain, and, at higher doses, QTc prolongation.
These events were dose dependent and reversible.123 Dy-
namic contrast enhanced magnetic resonance imaging in
patients, given ASA404 (500–4900 mg/m2) has demon-
strated a selective reduction in tumor blood flow.124 Based on
these results, further testing has been done with 1200 and
1800 mg/m2 of ASA404.
In a randomized phase Ib/II study, 78 patients with
previously untreated advanced stage NSCLC were treated
with carboplatin  paclitaxel alone, carboplatin  paclitaxel 
ASA404 1200 mg/m2 or carboplatin  paclitaxel  ASA404
1800 mg/m2; median survival was 8.8, 14.0, and 14.9 months,
respectively.125,126 In addition to expected toxicities, grade
TABLE 3. Tumor-Vascular Disrupting Agents
Molecules TNF  NO Tubulin Other Target
Flavonoids
FAA    
ASA404    
Tubulin-binding agents
CA4P    
ZD6126    
ABT-751    
AVE8062A    
OXi4503    
Dolostatin    
Auristatin    
Others
Thalidomide    
Exherin    N-cadherin
Cilengitide    Integrin
TNP-470    MAP
NPI-2358    Tubulin dimerization
NO, nitric oxide; FAA, flavone-8-acetic acid; MAP, methionine aminopeptidase.
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3/4 cardiac AEs occurred in 4 patients with ASA404 but only
in the 1200 mg/m2 arm (1 event each of angina pectoris,
cardiomyopathy, cardiovascular disorder and tachyarrhyth-
mia). There were no apparent differences in safety between
squamous and nonsquamous patients receiving ASA404 1800
mg/m2. These encouraging results have led to two ongoing
phase III trials: ATTRACT-1 randomizes previously un-
treated patients to carboplatin  paclitaxel with ASA404 or
placebo and ATTRACT-2 treats NSCLC with second-line
docetaxel with or without ASA404.127,128 Cardiac toxicity
will be closely monitored.
Tubulin-Binding Agents
CA4P, a water-soluble drug with similarity to colchi-
cine, is derived from the Cape Bushwillow tree Combretum
caffrum.129,130 It affects tubulin and actin filaments, leading to
increased permeability of the tumor vasculature among other
effects. In phase I and early phase II testing with the agent
given every once 3 weeks or daily for 5 days every 3 weeks,
the main AEs were tumor pain, pulmonary toxicity, nausea,
neuropathy, fatigue, hypotension, visual disturbances, and
acute coronary syndrome. Objective responses were reported
in a variety of tumor types.131–133 CA4P is currently in phase
II trials in combination with chemotherapy and radiotherapy.
Another colchicine analog, ZD6126, is a phosphate
prodrug that disrupts the tubulin cytoskeleton.134 In phase I
testing of the agent administered once every 3 weeks, AEs
were pain, anorexia, constipation, dyspnea, fatigue, headache,
nausea, vomiting, and cardiac ischemic events in addition to
increased intracranial pressure in two patients with active
brain metastases unsuspected at trial entry.135,136
ABT-751 also binds tubulin and is the furthest along in
lung cancer development of the colchicine analogs. Toxicities
in a phase I trial included neuropathy, constipation, fatigue,
myalgia, anemia, nausea, and vomiting.137 In the phase I
dose-escalation trial of ABT-751 and carboplatin in previ-
ously treated NSCLC, dose-limiting toxicities were thrombo-
cytopenia and neutropenia. Of the seven evaluable patients,
two had partial response, four had stable disease, and the
median TTP was 18.7 weeks. Some responses have been seen
in phase II monotherapy studies of previously treated
NSCLC, with toxicities similar to those seen in phase I.138
Other colchicine-disrupting agents in development in-
clude AVE8062A, a CA4P analog, and OXi4503, a prodrug
of combretastatin.139 The tubulin-binding agent dolastatin 10
and a derivative known as auristatin PE (TZT1027)140 are
also in early development.
Other Vascular Disrupting Agents
Based on activity of thalidomide (Celgene, Summit,
NJ) on the vasculature through TNF-, multiple phase I/II
trials of the compound in combination with chemotherapy
have been explored in NSCLC. A phase III trial of gemcit-
abine  carboplatin with or without thalidomide in 722
patients with stage IIIB/IV NSCLC observed a median sur-
vival for placebo and thalidomide arms of 8.9 and 8.4
months, respectively. More thrombotic events were observed
in the thalidomide arm, and it is unlikely this agent will be
explored further in NSCLC,141 though trials with analogs of
thalidomide (lenalidomide and pomalidomide, Celgene, Sum-
mit, NJ) are ongoing or being considered in SCLC. Two
phase III trials were done in patients with SCLC with thalid-
omide, but none of them found a benefit in survival for the
thalidomide arm.142,143
Different approaches to vascular targeting are repre-
sented by the following agents in early development: exherin,
an inhibitor of N-cadherin-mediated endothelial cell func-
tion144; cilengitide (Merck, Darmstadt, Germany), an integrin
inhibitor24,145; TNP-470 (Intergren Company, Purchase, NY),
an inhibitor of the endothelial cell proliferation enzyme
methionine aminopeptidase24,146; and NPI-2358 (Nereus
Pharmaceuticals Inc., San Diego, CA), an inhibitor of tubulin
dimerization (Table 3).
Given that TNF- plays a critical role in tumor vascu-
lature, it was studied in combination with chemotherapy for
mesothelioma without success.147 However, NGR-hTNF is
underdevelopment in Italy, primarily for the treatment of
SCLC with encouraging data to date. This prodrug compound
uses the effects of TNF- by combining it with the tumor
homing peptide, NGR.
One of the biggest challenges in developing compounds
that target vasculature is the lack of good correlative markers.
Although attempts have been made to find markers that
predict response to bevacizumab and the VEGFR-TKIs, they
have met with limited success. Soluble intercellular adhesion
molecule ICAM and VEGF levels have been found to be
prognostic but not predictive in the E4599 study with bev-
acizumab,148 and recent work with VEGF polymorphisms
have been intriguing, but not definitive.149 Circulating endo-
thelial cells may be predictive,150,151 and data with neuropilin
are encouraging.152
CONCLUSIONS
The potential therapeutic benefit of antiangiogenic
agents in lung cancer and other malignancies has now been
realized with the anti-VEGF antibody bevacizumab, and
other agents that target VEGF directly, along with multiple
agents targeting the VEGFR such as sorafenib, sunitinib,
vandetanib, and cediranib. The main toxicities are bleeding,
hypertension, skin rash, and diarrhea, and most agents have
shown increased toxicity in squamous cell histology. How
best to use these agents in which patients and in which
combination with other drugs remain areas of active investi-
gation. The hope is that tumor markers predictive of response
will soon be discovered to help improve the therapeutic
window with these drugs. The promise of cure initially
envisioned from mouse models with the antiangiogenic drugs
has yet to be realized, but they offer clear response and
progression benefits for numerous patients with NSCLC.
Another very exciting class of drugs targets the existing
tumor vasculature. These vascular disrupting agents, includ-
ing ASA404 and others earlier in development, work directly
on tumor vasculature leading to tumor necrosis. They have a
distinct toxicity profile with increased risk for cardiac toxicity
compared with the VEGF-targeted agents but very promising
randomized phase II efficacy data, and no differential toxicity
by histology has been noted to date. The results of ongoing
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phase III studies with these agents are eagerly awaited as
hope for better targeted drugs in lung cancer therapy persists.
Once the efficacy of these agents is established, combination
regimens of anti-VEGF and VDAs will be considered, which
may hold even further promise.
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